Oxygen Biotherapeutics, Inc. (OXBO.OB) Receives Go-Ahead for Phase II-B Trial
Yesterday, Oxygen Biotherapeutics, Inc. announced that the company has received approval from Israel's Ministry of Health to begin a Phase II-b clinical trial for use of Oxycyte(R), a perfluorocarbon therapeutic oxygen carrier, in traumatic brain injuries. With four centers in Israel, the clinical trial is part of a larger study that also includes seven trial centers in Switzerland. The company has named the study "Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury" or "STOP TBI." The dose escalation trial aims to discover the lowest possible dose of Oxycyte that provides clinical benefit in traumatic brain injury while…